New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

9

Biogen Bumps Up Diversity for Post-Marketing Aduhelm Trial

While the Centers for Medicare & Medicaid Services undergoes the comment period on its national coverage decision for Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab), Biogen and its partner company Eisai released additional details about the Phase IV post-marketing study of the drug.